^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    LPXN (Leupaxin)

    i
    Other names: LPXN, Leupaxin, LDPL, LDLP
    3ms
    The Leupaxin/HDAC6/EGR2 axis facilitates breast cancer progression by enhancing macrophage M2 polarization. (PubMed, Cell Biol Toxicol)
    These findings suggest LPXN may influence breast cancer progression through HDAC6/EGR2-mediated regulation of macrophage polarization. In conclusion, our study demonstrated that the LPXN/HDAC6/EGR2 axis promotes breast cancer progression by augmenting macrophage M2 polarization.
    Journal
    |
    HDAC6 (Histone Deacetylase 6) • LPXN (Leupaxin) • EGR2 (Early Growth Response 2)
    9ms
    SWI/SNF ATPase silenced HLF potentiates lung metastasis in solid cancers. (PubMed, Nat Commun)
    Overexpression of HLF or pharmacological inhibition of BRG1 reduces cell invasion across multiple cancer types. Our findings suggest that targeting the BRG1-HLF axis offers a promising therapeutic strategy for combating metastatic cancers.
    Journal
    |
    SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • LPXN (Leupaxin)
    1year
    Leupaxin promotes hepatic gluconeogenesis and glucose metabolism by coactivation with hepatic nuclear factor 4α. (PubMed, Mol Metab)
    Taken together, our study provides evidence that LPXN plays a critical role in modulating hepatic gluconeogenesis, thereby reinforcing the fact that targeting LPXN may be a potential approach for the treatment of diabetes and metabolic disorders.
    Journal
    |
    LPXN (Leupaxin) • GCG (Glucagon)
    |
    LPXN expression
    over1year
    Bioinformatics analysis of BTK expression in lung adenocarcinoma: implications for immune infiltration, prognostic biomarkers, and therapeutic targeting. (PubMed, 3 Biotech)
    We investigated the potential of BTK as a tumor suppressor gene in predicting prolonged patient survival. In addition, we further investigated the possibility that BTK further affects the immunotherapeutic response of patients by influencing the microenvironment of tumor immune infiltration, but the relevant mechanisms remain to be further studied.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • BTK (Bruton Tyrosine Kinase) • LAG3 (Lymphocyte Activating 3) • PD-L2 (Programmed Cell Death 1 Ligand 2) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD4 (CD4 Molecule) • LPXN (Leupaxin) • SIGLEC15 (Sialic Acid Binding Ig Like Lectin 15) • CD53 (CD53 Molecule) • ARHGAP30 (Rho GTPase Activating Protein 30)